Search
Alosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnAlosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured … Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes.
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigationalOne of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance
Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified _Escherichia coli_ bacteria. It is a 390-amino acid homodimer protein.
Epoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalThe sodium salt has been also used to treat primary pulmonary hypertension.
Ergocalciferol
go.drugbank.com/drugs/DB00153ApprovedInvestigationalNutraceutical[A177526] It is synthesized by some plants in the presence of UVB light. … [A177637] The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.[L6058]
Mixtures: Vitalipid N, Vitalipid NFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Ozenoxacin
go.drugbank.com/drugs/DB12924Approveds Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnIt has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. … voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTilactase
go.drugbank.com/drugs/DB13761ApprovedInvestigational[A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] … It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal.